In a study targeting endothelial integrin ligand ICAM-1, anti-ICAM-1 murine antibody was shown to be effective in experimental cerebral ischemia, but offered no neuroprotective benefits in the clinical phase III trial, rather was associated with adverse clinical outcomes [108]. Here, ICAM1 is linked to Cerebral ischemia.